A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type

Ji Jie; Liu Ting; Xiang Bing; Liu Weiping; He Chuan; Chen Xinchuan; Li Jianjun; Chang Hong; Dai Yang; Dong Tian

首页> 外文期刊>Leukemia and lymphoma >A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type

【24h】

A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type

机译：吉西他滨，L-天冬酰胺酶，异环磷酰胺，地塞米松和依托泊苷化学疗法用于新诊断的IV期，复发性或难治性结外自然杀伤/ T细胞淋巴瘤，鼻型的研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2014年第12期|共3页
作者
Ji Jie; Liu Ting; Xiang Bing; Liu Weiping; He Chuan; Chen Xinchuan; Li Jianjun; Chang Hong; Dai Yang; Dong Tian;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type [J] . Ji Jie, Liu Ting, Xiang Bing, Leukemia and lymphoma . 2014,第12期

机译：吉西他滨，L-天冬酰胺酶，异环磷酰胺，地塞米松和依托泊苷化学疗法用于新诊断的IV期，复发性或难治性结外自然杀伤/ T细胞淋巴瘤，鼻型的研究
2. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. [J] . Yamaguchi M, Suzuki R, Kwong YL, Cancer science. . 2008,第5期

机译：地塞米松，甲氨蝶呤，异环磷酰胺，L-天冬酰胺酶和依托泊苷（SMILE）化疗用于晚期，复发性或难治性结外自然杀手（NK）/ T细胞淋巴瘤和白血病的I期研究。
3. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. [J] . Yamaguchi M, Kwong YL, Kim WS, Journal of Clinical Oncology . 2011,第33期

机译：针对新诊断的IV期，复发性或难治性结外自然杀手（NK）/ T细胞淋巴瘤，鼻型的SMILE化疗的II期研究：NK细胞肿瘤研究组研究。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. A phase II prospective study of the Sandwich protocol L-asparaginase cisplatin dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin in newly diagnosed I/II stage nasal type extranodal natural killer/T-cell lymphoma [O] . Ming Jiang, Li Zhang, Li Xie, 2017

机译：在新诊断的I / II期鼻腔类型结外自然杀伤/ T细胞淋巴瘤中对三明治方案L-天冬酰胺酶顺铂地塞米松和依托泊苷化学疗法同时进行放疗和顺铂联合进行的II期前瞻性研究
6. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia [O] . Nakamura, S, Okamura, T, Suzumiya, J, 2008

机译：I期研究地塞米松，甲氨蝶呤，异环磷酰胺，1-天冬酰胺酶和依托泊苷（smILE）化疗治疗晚期，复发或难治性结外自然杀伤（NK）/ T细胞淋巴瘤和白血病

A study of gemcitabine, L-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type

著录项

相似文献

相关主题

期刊订阅